Related Experiment Video

Updated: Dec 8, 2025

A Zebrafish Model of Diabetes Mellitus and Metabolic Memory
10:03

A Zebrafish Model of Diabetes Mellitus and Metabolic Memory

Published on: February 28, 2013

26.3K

Effects of antidiabetic medications on cardiovascular outcomes

Marco Shiu Tsun Leung1, Shangzhe George Lin1, Leshanth Uthayanan1

  • 1Department of Surgery, Faculty of Medicine, University of London, St George's Hospital Medical School, London, United Kingdom.

Journal of Cardiac Surgery
|September 17, 2020
PubMed

Insights

Optimizing blood glucose levels with antidiabetic medications is crucial for reducing cardiovascular risks, especially in patients undergoing cardiac surgery. Further research is needed to fully understand medication impacts on cardiovascular safety.

Area of Science:

  • Cardiology
  • Endocrinology
  • Pharmacology

Background:

  • Hyperglycemia significantly elevates the risk of adverse cardiovascular outcomes, including heart failure, coronary heart disease, stroke, and in-hospital mortality.
  • Approximately 50% of patients undergoing cardiac surgery develop hyperglycemia, and 30% have pre-existing diabetes, a condition defined by chronic hyperglycemia.
  • Diabetes mellitus, characterized by chronic hyperglycemia, doubles the risk of cardiovascular events due to prothrombic states and endovascular damage.

Purpose of the Study:

  • To review the impact of antidiabetic medications on glycemic control and cardiovascular outcomes.
  • To synthesize current knowledge on the cardiovascular safety of antidiabetic drugs.

Main Methods:

  • An electronic literature search was conducted to identify relevant articles.
  • The search included articles discussing antidiabetic medications, their effects on glycemia, and cardiovascular outcomes.
  • Results were summarized narratively, without limitations on publication date or article type.

Main Results:

  • Antidiabetic medications are effective in lowering blood glucose, potentially reducing adverse cardiovascular outcomes.
  • Assessing the cardiovascular safety of these medications is complex due to confounding factors like age, obesity, smoking, hyperlipidemia, and hypertension.
  • Additional research is necessary to elucidate the precise correlation between antidiabetic medications and cardiovascular safety.

Conclusions:

  • Perioperative blood glucose optimization through appropriate medication and dosage is vital for minimizing morbidity.
  • Implementing measures to ensure safe blood glucose levels is essential for achieving optimal patient outcomes.
Abstract

Keywords:
antidiabeticscoronary arterial diseaseheart failurehyperglycemiastroke

More Related Videos

Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model06:22

Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model

Published on: November 29, 2024

1.1K
Glycemic Impact on Knee Osteoarthritis Symptoms on Physical, Radiographic, and Inflammatory Markers among Individuals Aged 50 and Over with Diabetes07:22

Glycemic Impact on Knee Osteoarthritis Symptoms on Physical, Radiographic, and Inflammatory Markers among Individuals Aged 50 and Over with Diabetes

Published on: March 7, 2025

571

Related Concept Videos

Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
502
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
434
Cardiovascular Drugs: Classification based on Therapeutic Indications01:18

Cardiovascular Drugs: Classification based on Therapeutic Indications

Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However,...
3.8K
Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
762
Antihypertensive Drugs: Vasodilators01:23

Antihypertensive Drugs: Vasodilators

Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
1.8K
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
428